The AGILE Clinical Team
AGILE is a collaboration between the University of Liverpool, Southampton Clinical Trials Unit, and other external partners. The team includes Infectious Diseases clinicians, clinical and pre-clinical pharmacologists, clinical trials specialists and statisticians, each bringing a unique set of skills and expertise to design the best platform possible.
Saye Khoo is Professor of Pharmacology and Therapeutics at the University of Liverpool and Honorary Consultant Physician in Infectious Disease at Liverpool University Hospitals NHS Foundation Trust. He leads a research programme in antiviral therapy and is Chief Investigator for the international DolPHIN consortium and for AGILE.
Lauren Walker is Senior Clinical Lecturer and Honorary Consultant in Clinical Pharmacology & Therapeutics and Associate Director of the NIHR Clinical Research Facility at Liverpool University Hospitals NHS Foundation Trust.
Tom Fletcher is Senior Clinical Lecturer at the Liverpool School of Tropical Medicine and a Defence Consultant in Infectious Diseases. He specialises in high consequence infectious diseases and is a long-term Consultant to the HQ WHO Clinical Team.
Richard FitzGerald is Director of the NIHR Clinical Research Facility and a Consultant Physician in Clinical Pharmacology and Therapeutics / General Medicine at the Liverpool University Hospitals NHS Foundation Trust.
Andrew Owen is Professor of Pharmacology and Director of the Centre of Excellence in Long-acting Therapeutics (CELT) at the University of Liverpool. He is Chair of the British Society for Nanomedicine, a fellow of the Royal Society of Biology, a fellow of the British Pharmacological Society, and a fellow of the Learned Society of Wales.
David Lalloo is Director and Professor of Tropical Medicine at the Liverpool School of Tropical Medicine. He has worked with the MLW Programme in Malawi for almost twenty years and holds an appointment as an Honorary Consultant at the Liverpool University Hospitals NHS Foundation Trust and remains clinically active.
Gareth Griffiths is the Director of the UKCRC registered Southampton Clinical Trials Unit (SCTU) and Professor of Clinical Trials based at the University of Southampton.
Sir Michael Jacobs
Michael Jacobs is Clinical Director of Infection at the Royal Free Hospital in London. He worked at the centre of the UK response to the West Africa Ebola outbreak, and serves on several national and international Ebola advisory committees. He was NHS England Programme Director for High Consequence Infectious Diseases.
Thomas Jaki is Professor of Statistics at Lancaster University and Programme Leader at the MRC Biostatistics Unit at the University of Cambridge. His work focuses on efficient trials using adaptive and Bayesian methods.
Helen Reynolds is a Programme Manager in Pharmacology and Therapeutics at the University of Liverpool and Honorary Clinical Research Nurse at Liverpool University Hospitals NHS Foundation Trust. She is a programme manager for the clinical trials in Prof. Saye Khoo’s antiviral research group that include the international DolPHIN consortium and AGILE.
Andrea Corkhill is Head of Trial Management at Southampton Clinical Trials Unit (SCTU). She has been working in clinical trials for more than 20 years, and has expertise in many aspects of clinical trial conduct. Andrea leads the trial management team within SCTU, with a particular focus on oncology and early phase COVID-19 clinical trials.
Michelle Tetlow is a Project Manager in Pharmacology and Therapeutics at the University of Liverpool. She has worked in clinical trials for over 20 years and has particular expertise within project and quality management, with an emphasis on setting up organisational quality systems.
Transparency and Conflicts of Interest
- Professor Saye Khoo has received research funding from ViiV, Merck, and Gilead unrelated to AGILE, support for the Liverpool Drug Interactions Resources from Viiv, Gilead, Merck, Janssen, Abbvie and speaker/consultancy fees from ViiV and Merck.
- Professor Andrew Owen is a Director and CSO for Tandem Nano Ltd and co-inventor of patents relating to drug delivery. AO has received research funding from ViiV Healthcare, Merck, and Janssen, as well as consultancy from Gilead, ViiV Healthcare and Merck not related to COVID19.
- Professor Gareth Griffiths has received funding from Janssen-Cilag, Astra Zeneca, Novartis, Astex, Roche, Heartflow, Celldex, BMS, BionTech, Cancer Research UK, NIHR, British Lung Foundation, GSK for unrelated academic clinical trials and programme funding.
- The Southampton Clinical Trials Unit has signed up to principles of AllTrials – https://www.alltrials.net/